• Cancel
    Date：2021-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=813

    On June 1, 2021, Stemirna announced the closing of a $200 million round of financing, led by China Merchants Capital, HongShan, King Lin investment, and WuXi AppTec, with participation from OrbiMed Advisors, Advantech Capital, Zhejiang Guotong Investment,

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=814

    HYGEIA (6078.HK) announced the acquisition of a 98% stake in Suzhou Yongding Hospital for a transaction size of RMB 1.7 billion. With this acquisition, Ascendent Capital, the controlling shareholder of Yongding Hospital, has completely divested its owners

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=815

    Genome Grecision, a rare domestic provider specializing in comprehensive molecular diagnostics solutions for hematological diseases, announced the closing of roughly RMB 200 million in Series C financing. This round of financing was jointly led by Sunland

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=566

    Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”) announces the completion of over 400M CNY Series-B financing round. The financing was led by GL Ventures, the venture capital unit of Hillhouse Capital, with participation from Cormorant Asset Management, VMS Group, and Heda Biopharmaceutical Venture Capital. The Series B financing round was also supported by existing investors, Sherpa Healthcare Partners and Oriental Fortune Capital. CEC Capital Group acted as the exclusive financial advisor in the transaction.

  • Cancel
    Date：2021-04

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=561

    Arrail Group (“Arrail” or the “Company), a leading dental service provider in China, announced that it has closed its Series E financing, with a transaction value of nearly $200M. The transaction was led by Temasek, with participation from OrbiMed, Ward Ferry, Hina Group, Industrial Bank and Mirae Asset. CEC Capital Group was the exclusive financial advisor on this transaction, and is proud to have advised Arrail since its Series A round of financing.

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=818

    The innovative artificial joint company b-ONE successfully closed a B-round financing of several hundred of million RMB, marking it the the largest RMB financing in the domestic orthopedic joint sector in recent years. The funding was led by Huatai Zijin

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=819

    On April 12, SUNING LSY announced the successful closing of a significant Series A financing with investment from CPE and ADV Partners. CEC Capital Group served as the exclusive financial advisor in this transaction for SUNING LSY.

  • Cancel
    Date：2021-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=560

    PALO ALTO, CA, March 30, 2021 -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1/2 financing. The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Funds Management, and existing investors, including Northern Light Venture Capital and Vivo Capital. In addition, the company received a strategic capital investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP), directed toward advancing the company’s work to treat blood cancers. CEC Capital Group was the exclusive financial advisor on this transaction.